Dirk Sibbing on The Importance of ISAR-REACT 5 trial and 2020 ESC Guidelines for ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Very impressive and important data published in EuroIntervention today, showing how impactful data from randomized trials can be…
In 2019, the randomized ISAR-REACT 5 trial demonstrated superiority of prasugrel over ticagrelor for treatment of ACS patients undergoing PCI
In consequence, the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation included a new COR IIa in preference for prasugrel for ACS-PCI
Then, an entire (!) country (Denmark) shifted treatment from routine use of ticagrelor over to prasugrel.
Results of this „real-life“ experiment are now published in Eurointervention
In 10,984 patients, prasugrel was associated with reduced 1-year rate of MACE (adjHR 0.67) and MI (adjHR 0.65), without differences in bleeding risk.
Risk reductions from randomized (ISAR-REACT 5) vs. observational data (Denmark) were very similar, thereby supporting current guideline recommendations
A great example for how impactful clinical trial data can be for the benefit of our patients.”
Read the full article here.
Article: Impact of shifting from routine use of ticagrelor to prasugrel in myocardial infarction patients after PCI: a nationwide cohort study
Authors: Mia Ravn Jacobsen, Peter Laursen Graversen, Reza Jabbari, Erik Lerkevang Grove, Charlotte Glinge, Lene Holmvang, Tobias Geisler, Lars Køber, Christian Torp-Pedersen, Thomas Engstrøm, Rikke Sørensen
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH